The licensing of life science technologies, especially oncology-related technologies, is becoming an essential part of doing business. With MedImmune v. Genentech, the United States Supreme Court transformed the relationship between patent licensors and licensees. Historically, licensees were prevented from challenging patents on invalidity grounds. Now, a licensee may challenge a patent's validity while paying royalties to the licensor.
Although framed as a procedural question of standing to bring suit, the application of this Supreme Court case has the potential to shift the decision making of licensors and licensees and to significantly change the volume and cost of patent licensing activities. In this audio conference Dr. Samardija explores the Supreme Court decision and the various decisions that have followed, and provides attendees with 10 drafting tips to decrease the risks associated with a licensee challenging the validity of a patent.
Effective Licensing in the Wake of MedImmune v. Genentech was presented by Michael R. Samardzija, PhD, with Bracewell & Giuliani and aired on 2009-01-29. For more details or to download this conference, please visit our site at www.fxconferences.com
Showing posts with label supreme court. Show all posts
Showing posts with label supreme court. Show all posts
Tuesday, June 9, 2009
Friday, January 9, 2009
Patent Portfolio Strategies in the Post-KSR Environment
Essential information for legal counsel and product development teams!
The Supreme Court’s decision in KSR v. Teleflex profoundly changed the landscape for biopharma companies and medical device manufacturers when it comes to building patent portfolios and managing them. More recently, the Federal Circuit’s Bilski decision in October 2008 added yet another dimension of complexity.
In this audio conference, we examine how this new environment changes the work of managers and professionals in product development teams, as well as patent professionals seeking to protect innovations. The presentation looks at how to identify and strengthen patents that might be vulnerable to obviousness attacks, and discusses ways to write and prosecute them to mitigate that risk.
Patent Portfolio Strategies in the Post-KSR Environment is being presented by Bruce D. Sunstein, Co-founder and Partner, with Bromberg & Sunstein LLP and airs on Thursday, February 12, 2009. For more details on this conference or to register, please visit our site www.fxconferences.com
The Supreme Court’s decision in KSR v. Teleflex profoundly changed the landscape for biopharma companies and medical device manufacturers when it comes to building patent portfolios and managing them. More recently, the Federal Circuit’s Bilski decision in October 2008 added yet another dimension of complexity.
In this audio conference, we examine how this new environment changes the work of managers and professionals in product development teams, as well as patent professionals seeking to protect innovations. The presentation looks at how to identify and strengthen patents that might be vulnerable to obviousness attacks, and discusses ways to write and prosecute them to mitigate that risk.
Patent Portfolio Strategies in the Post-KSR Environment is being presented by Bruce D. Sunstein, Co-founder and Partner, with Bromberg & Sunstein LLP and airs on Thursday, February 12, 2009. For more details on this conference or to register, please visit our site www.fxconferences.com
Tuesday, December 9, 2008
Effective Licensing in the Wake of MedImmune v. Genentech
The licensing of life science technologies, especially oncology-related technologies, is becoming an essential part of doing business. With MedImmune v. Genentech, the United States Supreme Court transformed the relationship between patent licensors and licensees. Historically, licensees were prevented from challenging patents on invalidity grounds. Now, a licensee may challenge a patent's validity while paying royalties to the licensor.
Although framed as a procedural question of standing to bring suit, the application of this Supreme Court case has the potential to shift the decision making of licensors and licensees and to significantly change the volume and cost of patent licensing activities. In this audio conference Dr. Samardija explores the Supreme Court decision and the various decisions that have followed, and provides attendees with 10 drafting tips to decrease the risks associated with a licensee challenging the validity of a patent.
Effective Licensing in the Wake of MedImmune v. Genentech is being presented by Michael R. Samardzija, PhD, with Bracewell & Giuliani and airs on Thursday, January 29, 2009. For more details, or to register for this conference please visit our web site at www.fxconferences.com
Although framed as a procedural question of standing to bring suit, the application of this Supreme Court case has the potential to shift the decision making of licensors and licensees and to significantly change the volume and cost of patent licensing activities. In this audio conference Dr. Samardija explores the Supreme Court decision and the various decisions that have followed, and provides attendees with 10 drafting tips to decrease the risks associated with a licensee challenging the validity of a patent.
Effective Licensing in the Wake of MedImmune v. Genentech is being presented by Michael R. Samardzija, PhD, with Bracewell & Giuliani and airs on Thursday, January 29, 2009. For more details, or to register for this conference please visit our web site at www.fxconferences.com
Subscribe to:
Posts (Atom)